IBDEI20N ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,33782,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33782,1,3,0)
 ;;=3^Arrhythmia,Cardiac,Unspec
 ;;^UTILITY(U,$J,358.3,33782,1,4,0)
 ;;=4^I49.9
 ;;^UTILITY(U,$J,358.3,33782,2)
 ;;=^5007237
 ;;^UTILITY(U,$J,358.3,33783,0)
 ;;=I13.0^^154^1704^9
 ;;^UTILITY(U,$J,358.3,33783,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33783,1,3,0)
 ;;=3^HTN Hrt Disease w/ Hrt Failure and CKD,Stage 1-4
 ;;^UTILITY(U,$J,358.3,33783,1,4,0)
 ;;=4^I13.0
 ;;^UTILITY(U,$J,358.3,33783,2)
 ;;=^5007067
 ;;^UTILITY(U,$J,358.3,33784,0)
 ;;=I13.2^^154^1704^10
 ;;^UTILITY(U,$J,358.3,33784,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33784,1,3,0)
 ;;=3^HTN Hrt Disease w/ Hrt Failure and CKD, Stage 5 or ESRD
 ;;^UTILITY(U,$J,358.3,33784,1,4,0)
 ;;=4^I13.2
 ;;^UTILITY(U,$J,358.3,33784,2)
 ;;=^5007070
 ;;^UTILITY(U,$J,358.3,33785,0)
 ;;=I13.10^^154^1704^11
 ;;^UTILITY(U,$J,358.3,33785,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33785,1,3,0)
 ;;=3^HTN Hrt Disease w/o Hrt Failure and CKD, Stage 1-4
 ;;^UTILITY(U,$J,358.3,33785,1,4,0)
 ;;=4^I13.10
 ;;^UTILITY(U,$J,358.3,33785,2)
 ;;=^5007068
 ;;^UTILITY(U,$J,358.3,33786,0)
 ;;=I13.11^^154^1704^12
 ;;^UTILITY(U,$J,358.3,33786,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33786,1,3,0)
 ;;=3^HTN Hrt Disease w/o Hrt Failure and CKD,Stage 5 or ESRD
 ;;^UTILITY(U,$J,358.3,33786,1,4,0)
 ;;=4^I13.11
 ;;^UTILITY(U,$J,358.3,33786,2)
 ;;=^5007069
 ;;^UTILITY(U,$J,358.3,33787,0)
 ;;=I50.1^^154^1704^15
 ;;^UTILITY(U,$J,358.3,33787,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33787,1,3,0)
 ;;=3^Left Ventricular Failure
 ;;^UTILITY(U,$J,358.3,33787,1,4,0)
 ;;=4^I50.1
 ;;^UTILITY(U,$J,358.3,33787,2)
 ;;=^5007238
 ;;^UTILITY(U,$J,358.3,33788,0)
 ;;=E21.3^^154^1705^17
 ;;^UTILITY(U,$J,358.3,33788,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33788,1,3,0)
 ;;=3^Hyperparathyroidism,Unspec
 ;;^UTILITY(U,$J,358.3,33788,1,4,0)
 ;;=4^E21.3
 ;;^UTILITY(U,$J,358.3,33788,2)
 ;;=^331438
 ;;^UTILITY(U,$J,358.3,33789,0)
 ;;=E78.5^^154^1705^16
 ;;^UTILITY(U,$J,358.3,33789,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33789,1,3,0)
 ;;=3^Hyperlipidemia,Unspec
 ;;^UTILITY(U,$J,358.3,33789,1,4,0)
 ;;=4^E78.5
 ;;^UTILITY(U,$J,358.3,33789,2)
 ;;=^5002969
 ;;^UTILITY(U,$J,358.3,33790,0)
 ;;=M10.30^^154^1705^11
 ;;^UTILITY(U,$J,358.3,33790,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33790,1,3,0)
 ;;=3^Gout d/t Renal Impairment,Unspec Site
 ;;^UTILITY(U,$J,358.3,33790,1,4,0)
 ;;=4^M10.30
 ;;^UTILITY(U,$J,358.3,33790,2)
 ;;=^5010356
 ;;^UTILITY(U,$J,358.3,33791,0)
 ;;=E66.9^^154^1705^33
 ;;^UTILITY(U,$J,358.3,33791,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33791,1,3,0)
 ;;=3^Obesity,Unspec
 ;;^UTILITY(U,$J,358.3,33791,1,4,0)
 ;;=4^E66.9
 ;;^UTILITY(U,$J,358.3,33791,2)
 ;;=^5002832
 ;;^UTILITY(U,$J,358.3,33792,0)
 ;;=E66.01^^154^1705^32
 ;;^UTILITY(U,$J,358.3,33792,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33792,1,3,0)
 ;;=3^Obesity,Morbid,d/t Excess Calories
 ;;^UTILITY(U,$J,358.3,33792,1,4,0)
 ;;=4^E66.01
 ;;^UTILITY(U,$J,358.3,33792,2)
 ;;=^5002826
 ;;^UTILITY(U,$J,358.3,33793,0)
 ;;=D50.9^^154^1705^2
 ;;^UTILITY(U,$J,358.3,33793,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33793,1,3,0)
 ;;=3^Anemia,Iron Deficiency,Unspec
 ;;^UTILITY(U,$J,358.3,33793,1,4,0)
 ;;=4^D50.9
 ;;^UTILITY(U,$J,358.3,33793,2)
 ;;=^5002283
 ;;^UTILITY(U,$J,358.3,33794,0)
 ;;=D63.1^^154^1705^1
 ;;^UTILITY(U,$J,358.3,33794,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33794,1,3,0)
 ;;=3^Anemia in Chronic Kidney Disease
 ;;^UTILITY(U,$J,358.3,33794,1,4,0)
 ;;=4^D63.1
 ;;^UTILITY(U,$J,358.3,33794,2)
 ;;=^332908
 ;;^UTILITY(U,$J,358.3,33795,0)
 ;;=G60.9^^154^1705^31
